Perspective Therapeutics, Inc. (CATX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol CATX
- Company Perspective Therapeutics, Inc.
- Price $5.02
- Changes Percentage -0.89
- Change -0.05
- Day Low $4.91
- Day High $5.68
- Year High $6.16
- Year Low $1.6
- Market Cap $372,805,020
- Price Avg 50 EMA (D) $2.66
- Price Avg 200 EMA (D) $3.09
- Exchange AMEX
- Volume 5,312,506
- Average Volume 3,288,286
- Open $5
- Previous Close $5.06
- EPS -1.34
- PE -3.74
- Earnings Announcement 2026-03-26 12:00:00
- Shares Outstanding $74,337,990
Company brief: PERSPECTIVE THERAPEUTICS, INC. (CATX )
- Healthcare
- Medical - Devices
- Mr. Johan M. Spoor
- https://www.perspectivetherapeutics.com
- US
- N/A
- 11-10-2005
- US46489V1044
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
CATX Corporation News
Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
globenewswire.com -- SEATTLE, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced trea...